BAC Shorts Inch Up as Analysts Trim Targets and Stock Lags Peers

Short sellers have added modestly to their Bank of America position over the past month, pushing shares short from roughly 82.4 million to 86.9 million. That puts short interest at 1.2% of the free float, up about 4% over 30 days and 1.3% on the week. The move is real but not dramatic. At 1.2% of float, this remains a lightly shorted stock by any standard.

The borrow market confirms there is no urgency in that short buildup. Borrowing costs have collapsed, falling from around 0.48% at the start of October to just 0.064% now, a drop of roughly 85% over the month. Availability is effectively unlimited. The options market is similarly calm: the put/call ratio of 1.17 is essentially flat to its 20-day average of 1.17, with a z-score near zero. Taken together, the positioning picture is one of mild, gradual short accumulation against a borrow market that offers no friction and an options market showing no unusual hedging demand.

The more interesting story is the gap between where analysts think the stock belongs and where it trades. BAC closed at $49.66 on Tuesday, down 2% on the week. The consensus price target is $62.47, implying roughly 26% upside. The Street has not abandoned its ratings: following the Q3 earnings print in October, every major firm that cut targets kept its positive rating. UBS lowered its target from $67 to $62 while holding Buy. JP Morgan trimmed from $62 to $59.50 at Overweight. Morgan Stanley cut from $67 to $61 at Overweight. Barclays moved from $72 to $68, also at Overweight. The pattern is consistent: a uniform downward revision in price targets after earnings, but no rating changes. The Street is recalibrating its level of optimism, not its direction. Factor scores back the constructive lean: the analyst recommendation differential ranks in the 90th percentile, and the dividend score also sits at 90.

That gap between target and price has opened because the stock has moved faster than analysts have adjusted. BAC is down about 7.6% over the past month. The peer group has not followed. This week, Wells Fargo gained 3.5% and JPMorgan added 0.7%. Citizens Financial is the only close peer also in the red on the week, down 1.4%. The valuation has compressed as a result: price-to-book is now 1.17x, down roughly 0.10x over 30 days, and the trailing P/E has eased to 9.8x. On both measures, BAC looks cheaper relative to itself than it did a month ago, but the market has not yet treated the compression as a signal to buy.

The company's own data from ORTEX Alt Data adds some texture. FDIC call report data shows net loans and leases have risen for nine consecutive quarters, with the most recent reading at $1.21 trillion. Total deposits hit a record for any second quarter in the dataset's history, reaching $2.13 trillion as of June 30. Buyback spend in Q2 was $6 billion, up 13% on the same quarter last year and the largest Q2 figure in six years. Neither the FDIC series nor the ABS trust data has been tested as a leading indicator of BAC's reported figures, so these readings describe the business as it has been, not where it is heading.

The next earnings event is scheduled for January 15, 2027, 72 days away. Between now and then, the question the data leaves open is whether the valuation gap narrows because the stock recovers toward the consensus target, or because analysts continue lowering targets toward the price.